Manipulation of T cell response to tumors by targeting on costimulatory pathway

Leukemia

Volumn 11, Issue SUPPL. 3, 1997, Pages 567-569

  Chen, Lieping ^a  

^a BRISTOL MYERS SQUIBB PHARMACEUTICAL RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD2 ANTIGEN; MAJOR HISTOCOMPATIBILITY ANTIGEN; T LYMPHOCYTE RECEPTOR;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; CELLULAR IMMUNITY; CONFERENCE PAPER; IMMUNOGENICITY; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR IMMUNITY; TUMOR REGRESSION;

EID: 0030816211     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Mueller, DL et al. Clonal expansion versus functional clonal inactivation: A costimulatory signaling pathway determines the outcome of T cell antigen receptor occupancy. Ann Rev Immunol, 1989; 7: 445-480.
2. Linsley, PS and Ledbetter JA. The role of the CD28 receptor during T cell responses to antigen. Ann Rev Immunol, 1993; 11: 191-212.
3. Chen, L et al. Tumor immunogenicity determines the effect of B7 costimulation on T cell-mediated tumor immunity. J Exp Med, 1994; 179: 523-532.
4. Chen, L et al. Costimulation of T cells for tumor immunity. Immunol Today, 1993; 14: 483-496.
5. Hellström KE et al. Can co-stimulated tumor immunity be therapeutically efficacious? Immunol Rev, 1995; 145: 123-145.